Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-NODAGA-SNA006 PET/CT in solid tumors or lymphoma
NCT07059832Phase 2Active, not recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Apr 2024
- Primary completion
- Jan 2028
- Modality
- Nanobodies (VHH), Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of 68Ga-NODAGA-SNA006 in solid tumor, lymphoma, sponsored by First Hospital of China Medical University. Started Apr 2024; status: active, not recruiting.
02
Drugs
68Ga-NODAGA-SNA006
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT07059832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07059832.